BionicMimics™ Platform
Inflammatory/Autoimmune Diseases
DiscoveryActive
Key Facts
Indication
Inflammatory/Autoimmune Diseases
Phase
Discovery
Status
Active
Company
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. is a clinical-stage biotech company with a dual mission: advancing its own pipeline of antibody therapies for infectious and autoimmune diseases while operating a contract development and manufacturing organization (CDMO) to fund its research. Its key strategic asset is a state-of-the-art cGMP biologics manufacturing facility in Jerusalem, providing end-to-end control from discovery to production. The company's public listings on NASDAQ (SCNI) and the Tel Aviv Stock Exchange support its goal of leveraging service revenue to de-risk and accelerate its proprietary drug development programs.
View full company profileTherapeutic Areas
Other Inflammatory/Autoimmune Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Immunometabolism Program(s) | Inapill | Preclinical |
| NAV-242 | Navigator Medicines | Phase 1 |
| A2AR PAM | Adoram Therapeutics | Hit-to-Lead |
| CAN10 | Cantargia | Phase I (Completed) |
| CAN14 | Cantargia | Preclinical |